- Home
- APLT vs RDFN Comparison
APLT vs RDFN Comparison
Compare APLT & RDFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- RDFN
- Stock Information
- Founded
- APLT 2016
- RDFN 2002
- Country
- APLT United States
- RDFN United States
- Employees
- APLT N/A
- RDFN N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- RDFN Real Estate
- Sector
- APLT Health Care
- RDFN Finance
- Exchange
- APLT Nasdaq
- RDFN Nasdaq
- Market Cap
- APLT 971.6M
- RDFN 936.1M
- IPO Year
- APLT 2019
- RDFN 2017
- Fundamental
- Price
- APLT $8.69
- RDFN $8.37
- Analyst Decision
- APLT Strong Buy
- RDFN Hold
- Analyst Count
- APLT 5
- RDFN 11
- Target Price
- APLT $12.50
- RDFN $9.23
- AVG Volume (30 Days)
- APLT 1.8M
- RDFN 6.1M
- Earning Date
- APLT 11-07-2024
- RDFN 11-07-2024
- Dividend Yield
- APLT N/A
- RDFN N/A
- EPS Growth
- APLT N/A
- RDFN N/A
- EPS
- APLT N/A
- RDFN N/A
- Revenue
- APLT N/A
- RDFN $1,016,774,000.00
- Revenue This Year
- APLT N/A
- RDFN $8.63
- Revenue Next Year
- APLT $3,169.03
- RDFN $10.93
- P/E Ratio
- APLT N/A
- RDFN N/A
- Revenue Growth
- APLT N/A
- RDFN 3.70
- 52 Week Low
- APLT $1.79
- RDFN $5.10
- 52 Week High
- APLT $10.62
- RDFN $15.29
- Technical
- Relative Strength Index (RSI)
- APLT 46.34
- RDFN 34.14
- Support Level
- APLT $9.44
- RDFN $10.14
- Resistance Level
- APLT $10.62
- RDFN $11.88
- Average True Range (ATR)
- APLT 0.62
- RDFN 0.70
- MACD
- APLT -0.13
- RDFN -0.20
- Stochastic Oscillator
- APLT 14.95
- RDFN 0.57
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.